Sustained Treatment of Type 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title:

Applicant(s): Habib Zaghouani, et al.

App. No.: 10/681,788

Conf. No.: 6701

Filing Date: October 8, 2003

Diabetes After Expression of

Predisposition Markers

1644 Art Unit:

Examiner: Edwoldt, Gerald R.

Commissioner for Patents PO BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

Response to Official Communication

In response to the Official Communication dated January 19, 2007, Applicants submit via the Electronic Filing System the following:

Computer – Readable format of Sequence Listing

I hereby state that the sequence listing information recorded in computer readable form submitted herewith does not extend beyond the original disclosure.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing the above-identified docket number.

By:

Respectfully submitted,

HOWREY LLP

Dated: February 9, 2007

David B. Fournier

Registration No.: 51,696 Customer No.: 22930

Telephone No.: (312) 846-5621

HOWREY LLP

ATTN: Docketing Department 2941 Fairview Park Drive, Suite 200

Falls Church, VA 22042-9922 Telephone No.: (703) 663-3600 Facsimile No.: (703) 336-6950